Crinetics Pharmaceuticals Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
84.95 0.13
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
84.95
Max
84.95
Pajamos | 7M -121M |
|---|---|
Pardavimai | 14M 25M |
Pelnas, tenkantis vienai akcijai | -1.14 |
Pelno marža | -481.149 |
Darbuotojai | 594 |
EBITDA | -4.7M -131M |
Rekomendacijos | Neutralu |
|---|---|
12 mėnesių prognozė | +0.72% upside |
Rinkos kapitalizacija | 148M 9B |
|---|---|
Ankstesnė atidarymo kaina | 84.82 |
Ankstesnė uždarymo kaina | 84.95 |
Crinetics Pharmaceuticals Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Crinetics Pharmaceuticals Inc Prognozė
Kainos tikslas
By TipRanks
0.72% į viršų
12 mėnesių prognozė
Vidutinis 85.56 USD 0.72%
Aukščiausias 95 USD
Žemiausias 80 USD
Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.
Finansinės naujienos
$
Apie bendrovę Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
